MENU

AstraZeneca plc Doubles Down On Diabetes With $4.1bn Buyout

To find out the names of five shares in the FTSE 100 that our top analysts have highlighted in our special report “5 Shares To Retire On“, and the reasons behind their inclusion, simply click here to have it delivered free to your inbox.

In this investing video, Owain Bennallack analyses AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) deal with US company Bristol-Myers Squibb to acquire ownership of the pair’s diabetes treatment joint venture.

> Owain owns shares in AstraZeneca.